title: Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps.
abstract: Decline in hippocampal-dependent explicit memory (memory for facts and events) is one of the earliest clinical symptom of Alzheimer's disease (AD). It is well established that synapse loss and ensuing neurodegeneration are the best predictors for memory impairments in AD. Latest studies have emphasized the neurotoxic role of soluble amyloid-beta oligomers (Aβo) that begin to accumulate in the human brain approximately 10 to 15 yr before the clinical symptoms become apparent. Many reports indicate that soluble Aβo correlate with memory deficits in AD models and humans. The Aβo-induced neurodegeneration observed in neuronal and brain slice cultures has been more challenging to reproduce in many animal models. The model of repeated Aβo infusions shown here overcome this issue and allow addressing two key domains for developing new disease modifying therapies: identify biological markers to diagnose early AD, and determine the molecular mechanisms underpinning Aβo-induced memory deficits at the onset of AD. Since soluble Aβo aggregate relatively fast into insoluble Aβ fibrils that correlate poorly with the clinical state of patients, soluble Aβo are prepared freshly and injected once per day during six days to produce marked cell death in the hippocampus. We used cannula specially design for simultaneous infusions of Aβo and continuous infusion of Aβo antibody (6E10) in the hippocampus using osmotic pumps. This innovative in vivo method can now be used in preclinical studies to validate the efficiency of new AD therapies that might prevent the deposition and neurotoxicity of Aβo in pre-dementia patients.
authors: Department of Pharmacology, Université de Montréal; Hôpital du Sacré-coeur de Montréal Research Center, Université de Montréal.
authors: Ahmadali
authors: A
authors: Sajadi
authors: Hôpital du Sacré-coeur de Montréal Research Center, Université de Montréal.
authors: Chloé
authors: C
authors: Provost
authors: Department of Neuroscience, Université de Montréal.
authors: Brendon
authors: B
authors: Pham
authors: Department of Pharmacology, Université de Montréal; Hôpital du Sacré-coeur de Montréal Research Center, Université de Montréal; jonathan.brouillette@umontreal.ca.
authors: Jonathan
authors: J
authors: Brouillette
mesh_terms: D000544:Alzheimer Disease / Q000503:physiopathology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000009:adverse effects; D000818:Animals; D004195:Disease Models, Animal; D006624:Hippocampus; D006801:Humans; D008569:Memory Disorders; D009474:Neurons
chemical_list: D016229:Amyloid beta-Peptides